Circassia said PAP-1, a novel topical therapeutic for psoriasis and atopic dermatitis, is a highly specific immunosuppressant and a selective Kv1.3 inhibitor that has ideal topical delivery characteristics.
It acts on effector memory T-cells only leaving naive and central memory T-cells intact, and has shown remarkable activity in psoriasis and atopic dermatitis models when topically applied, according to the company.
Circassia R&D vice president Rod Hafner said PAP-1’s selective immunosuppression coupled with its topical delivery characteristics make it ideal as a psoriasis and atopic dermatitis treatment.
Airmid CEO George Miljanich said out-licensing topical PAP-1 is a major milestone for Airmid and they are delighted to have attracted a team of Circassia’s high caliber to progress its development.